Výsledky vyhledávání - "Alice R. Lim"

Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer

Autor: Violeta Serra, Alice R. Lim, José Antonio Jiménez, Kelly Slocum, Olga Graciela Cantu Rodriguez, Maurizio Scaltriti, Marta Guzman, Varenka Rodriguez, José Baselga, Claudia Aura, Ludmila Prudkin, Kip A. West, Emmanuel Normant

Publikováno v: Molecular Cancer Therapeutics. 10:817-824

Hsp90 facilitates the maturation and stability of numerous oncoproteins, including HER2. The aim of this study was to assess the antitumor activity of the Hsp90 inhibitor IPI-504 in trastuzumab-resistant, HER2-overexpressing breast cancer cells. Ther

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26e5c69294d7f42b4412b2b7f65e15a1
https://doi.org/10.1158/1535-7163.mct-10-0966

Zobrazit plný text záznamu

Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors

Autor: Alice R. Lim, Matthias Ocker, Michael Höpfner, Evan Vosburgh, Hans Scherübl, Bianca Nitzsche, Mark Schrader, Emmanuel Normant, C Gloesenkamp

Publikováno v: International journal of oncology. 40(5)

Treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NET) is still unsatisfactory and innovative therapeutic approaches are urgently needed. Heat shock protein 90 (Hsp90) is overexpressed in a wide range of tumor types and is an emerging ta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b625c2ff3a593d4c38f220ab798bfda0
https://pubmed.ncbi.nlm.nih.gov/22246317

Zobrazit plný text záznamu

The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo

Autor: Christian C. Fritz, Julian Adams, Melissa Pink, Jie Ge, Michael Curtis, Emmanuel Normant, Thomas T. Tibbits, James R. Porter, Andrew Wylie, Mark Douglas, Kurtis Biggs, Kip A. West, Vito J. Palombella, Alice R. Lim

Publikováno v: Molecular cancer therapeutics. 8(12)

IPI-504, a water-soluble ansamycin analogue currently being investigated in clinical trials, is a potent inhibitor of the protein chaperone heat shock protein 90 (Hsp90). Inhibition of Hsp90 by IPI-504 triggers the degradation of important oncogenic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6be9a591308cbb7ce46be845eaba39b7
https://pubmed.ncbi.nlm.nih.gov/19952119

Zobrazit plný text záznamu

CD8(-) T cell transfectants that express a high affinity T cell receptor exhibit enhanced peptide-dependent activation

Autor: Laurie A. Rund, Phillip D. Holler, Alice R. Lim, Bryan K. Cho, David M. Kranz

Publikováno v: The Journal of Experimental Medicine

T cells are activated by binding of the T cell receptor (TCR) to a peptide-major histocompatibility complex (MHC) complex (pMHC) expressed on the surface of antigen presenting cells. Various models have predicted that activation is limited to a narro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa8e14779b81c736953a7c0a81020206
https://pubmed.ncbi.nlm.nih.gov/11602635

Zobrazit plný text záznamu

Abstract A215: Hsp90 inhibitor IPI-504 demonstrates antitumor activity against a panel of neuroendocrine/carcinoid cell lines in vitro and in vivo

Autor: Igor Denyeko, Evan Vosburgh, Alice R. Lim, Emmanuel Normant, Kelly Slocum, Christian Fritz, Kip A. West, Vito J. Palombella

Publikováno v: Molecular Cancer Therapeutics. 8:A215-A215

Heat shock protein 90 (Hsp90), an emerging target in cancer, is a chaperone protein that contributes to tumorigenesis by maintaining the stability and activity of multiple oncogenic proteins. Infinity Pharmaceuticals is currently developing two Hsp90

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::63249d67f22bd109d7e9839be5a4f082
https://doi.org/10.1158/1535-7163.targ-09-a215

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání